What Tirzepatide actually is
Tirzepatide is a synthetic peptide of 39 amino acids, designed from the ground up at Eli Lilly to act on two different incretin receptors at the same time. The "incretin" hormones are gut peptides released after a meal that drive a glucose-dependent insulin response in the pancreas, plus a wider set of effects on satiety, gastric emptying, and adipocyte function. There are two of them: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Earlier metabolic-research compounds in the same family targeted GLP-1 alone. Tirzepatide is the first published twincretin to reach late-stage clinical development.
The molecule is built on the GIP backbone with selected residue substitutions and two non-natural alpha-aminoisobutyric-acid (Aib) residues at positions 2 and 13. Those Aib substitutions are a standard trick in modern peptide design: they replace a normal alpha carbon with one that is sterically hindered and not recognised by the proteases that would otherwise degrade the molecule. The result is a chimeric sequence whose backbone is recognised by both the GIP and GLP-1 receptors. Single sequence, two targets, one engineering choice that defines the compound.
| Length | 39 amino acids (with C-terminal amide) |
| Average MW | 4813.53 g/mol |
| Non-natural residues | Aib at positions 2 and 13 (alpha-aminoisobutyric acid, protease-resistant) |
| Lipid modification | C20 fatty diacid attached at Lys20 via gamma-Glu plus 2 x AEEA spacer |
| Receptor profile | Dual GIP receptor + GLP-1 receptor agonist (twincretin) |
| Half-life | ~5 days (~120 hours), enables once-weekly subcutaneous administration in published research literature |
| Albumin binding | High, mediated by the C20 fatty acid; the dominant clearance-slowing mechanism |
| Lyophilised stability | 24+ months at 2–8 °C, sealed and protected from light |
Why dual GIP plus GLP-1 mattered
The twincretin idea, in one paragraph.
For two decades the metabolic-research conventional wisdom was that GIP was a dead end. People with type 2 diabetes have a blunted GIP response in the published clinical literature, and the assumption was that you couldn't usefully agonise a receptor whose signalling was already broken. The reframe that drove tirzepatide was that the GIP defect in type 2 diabetes appears to be functional rather than structural: hit the receptor with a designed dual agonist that also restores normal glycaemic control via GLP-1 agonism, and the GIP arm starts contributing in directions that single-target GLP-1 agonism does not.
What you get on the published-trial endpoints is a combination effect that is consistently larger than the GLP-1-only comparator at matched doses. The clearest demonstration was SURPASS-2, the head-to-head against semaglutide. Tirzepatide beat it. That is the single most important data point for understanding why the molecule reshaped the entire research conversation in this category.
The chemistry behind the once-weekly half-life
A bare 39-amino-acid peptide injected into the body would be cleared in hours. Modern long-acting peptide design solves this with a lipid modification that hijacks the abundance of serum albumin, the most plentiful protein in plasma. The fatty acid sticks to albumin reversibly, which dramatically slows the rate at which the molecule is cleared by the kidneys.
For tirzepatide, the modification is a C20 fatty diacid (a 20-carbon dicarboxylic acid chain) attached to the side chain of lysine 20 through a linker built from a gamma-glutamic-acid residue plus two units of AEEA (8-amino-3,6-dioxaoctanoic acid). The same chemistry concept appears across the family of long-acting peptides: semaglutide uses a C18 diacid with a similar linker arrangement, and retatrutide uses its own variation. The choice of chain length, linker length, and attachment residue is the technical lever that determines exactly how long the molecule sits in circulation.
For the bench scientist, the practical implication is that tirzepatide reconstitutes cleanly into a clear colourless solution and behaves as a long-half-life lipopeptide in any research model that involves serum albumin. The molecule is not unusually fragile but it does have specific handling preferences (cold chain, amber glass, no shaking) that the lipid modification reinforces, since shear and foaming can affect the lipid micellisation behaviour of the reconstituted solution.
The SURPASS and SURMOUNT trial data
The phase 3 programme was, in scale and pace, one of the more ambitious published peptide development programmes of the last decade. Two parallel series:
SURPASS (type 2 diabetes)
Five trials in adults with type 2 diabetes, against placebo, semaglutide, insulin glargine, and insulin degludec. The pivotal head-to-head was SURPASS-2 (Frias et al., NEJM 2021, PMID 34170647) which compared tirzepatide 5, 10 and 15 mg weekly against semaglutide 1 mg weekly. Tirzepatide produced larger reductions in HbA1c and in body weight at every dose level.
SURMOUNT-1 (obesity, no diabetes)
72-week trial in adults with obesity but without type 2 diabetes, published as Jastreboff et al. NEJM 2022, PMID 35658024. The headline numbers are the ones that propagated through the entire metabolic-research conversation:
| Arm | Mean body-weight change at 72 weeks | Loss ≥5% of body weight |
|---|---|---|
| Placebo | −3.1 % | ~35% |
| Tirzepatide 5 mg/wk | −15.0 % | ~85% |
| Tirzepatide 10 mg/wk | −19.5 % | ~89% |
| Tirzepatide 15 mg/wk | −20.9 % | ~91% |
SURMOUNT-2 (in adults with type 2 diabetes plus obesity) reported a mean reduction of 14.7 percent at the 15 mg dose. SURMOUNT-3 (after intensive lifestyle intervention) and SURMOUNT-4 (continued treatment vs withdrawal) round out the obesity programme.
The licensing followed quickly. The FDA authorised Eli Lilly's branded product, Mounjaro, for type 2 diabetes in May 2022. Zepbound, the same molecule under a different brand for chronic weight management, followed in November 2023. The MHRA authorised Mounjaro for type 2 diabetes in the UK and the product is now NHS-funded for patients meeting the relevant clinical criteria.
What to look for on the Certificate of Analysis
If you've read our walk-through of how to read a Janoshik HPLC report, the standard structure applies. For tirzepatide specifically, three things matter:
1. A single tall peak on the reversed-phase HPLC chromatogram
You want one dominant peak at the tirzepatide retention time, a flat baseline elsewhere, and 99%+ purity in the analytical summary. The tirzepatide market is the most actively counterfeited peptide segment globally right now, so the chromatogram trace itself matters more than the headline number. A report that quotes 99% purity but never shows you the trace is giving you a number you cannot verify.
2. Mass-spectrometry confirmation of the 4813.53 g/mol mass
Tirzepatide is large enough that on electrospray mass spectra you see multiply-charged species rather than a single intact molecular ion. The typical positive-ion charge states are [M+3H]3+ at m/z 1605.5, [M+4H]4+ at m/z 1204.4, [M+5H]5+ at m/z 963.7, and [M+6H]6+ at m/z 803.3. A real spectrum from Janoshik or any competent peptide-analysis lab will show a characteristic ladder of these charge states with the masses cross-summable back to 4813.53 g/mol average.
3. The Janoshik verification key resolves on their portal
Every Janoshik certificate carries a short alphanumeric verification key. That key, plus the task ID printed on the certificate, can be cross-referenced on the issuing lab's public records. A real tirzepatide batch will resolve. A fabricated COA will not. Do this check yourself; do not take "verified" as a self-assertion from the supplier.
Storage and handling at your bench
- Refrigerate at 2–8 °C in the original sealed amber-glass vial. Tirzepatide is stable for 24 months or more in the lyophilised state when kept dry, sealed, and protected from light.
- Reconstitute with bacteriostatic water by adding the water slowly down the inside wall of the vial and gently swirling (not shaking, never vortexing) until the cake fully dissolves. The resulting solution should be clear and colourless. Cloudiness suggests undissolved peptide or contamination.
- Reconstituted shelf life is shorter than the lyophilised form. The published preclinical analytical literature commonly references stability over a window of four to six weeks under refrigeration; consult the specific assay or research method you are running for the exact figure for your context.
- Avoid freeze-thaw cycles on the reconstituted solution. The lipid modification makes tirzepatide micelle-prone and repeated freeze-thaw is the single most common cause of a previously good vial dropping in measurable activity.
- Ship and store in amber glass. Tirzepatide is less photolabile than copper-coordinated peptides like GHK-Cu, but cold-chain amber-glass shipping is the right default for any modern lipopeptide.
Common red flags when sourcing tirzepatide
Walk-away signals when buying tirzepatide
- The lyophilised cake in the supplier's product photos is yellowed, cream-coloured, or shown as a heap of loose granular powder rather than a uniform porous white cake. Tirzepatide done correctly produces a clean white puck.
- No batch-specific Certificate of Analysis included with the order. The tirzepatide market is the most actively counterfeited peptide segment globally; a generic "we test our products" line on the website is not the same as a per-batch COA tied to the vial in your hand.
- The COA carries no verification key, or the key does not resolve on the issuing lab's public portal. Cross-check it yourself.
- Mass-spectrometry data is absent or shows only one of the multiply-charged species in isolation. A real tirzepatide spectrum has a characteristic multi-charge-state ladder; a single peak in isolation is not strong evidence of identity.
- The chromatogram (if shown) has multiple peaks of comparable height. Tirzepatide synthesis is genuinely difficult, and a chromatogram with a single dominant peak plus minor impurities is the correct shape; a chromatogram with several near-equal peaks usually means a mixed synthesis product.
- The supplier markets "tirzepatide" oral capsules, sublingual sprays, or topical creams. These formats are inconsistent with the published research literature on tirzepatide, are outside the research-reagent supply category we operate in, and are a near-universal indicator of a non-reputable seller.
- Pricing is far below the broader market rate. Tirzepatide is not a cheap peptide to synthesise and purify correctly to 99%+. A vial advertised at a fraction of the market rate is, more often than not, a vial of something else (often an older, easier-to-synthesise GLP-1 analogue) with a tirzepatide label on it.
- Vial label has no batch number, no fill weight, or no manufacturer identifier. Trade-grade reference reagent always has this on the label.
Where this fits in the metabolic-research family
Tirzepatide sits between earlier GLP-1-only compounds and the newer triple agonists. The closest peers in the catalogue are semaglutide (single-target GLP-1, the previous market standard) and retatrutide (the triple agonist that adds glucagon-receptor activity to the GIP and GLP-1 stack). Our side-by-side write-ups cover the trade-offs:
- Tirzepatide vs Semaglutide - dual incretin vs single-target GLP-1
- Tirzepatide vs Retatrutide - dual vs triple receptor agonism
- Semaglutide vs Retatrutide - single vs triple agonist for context
What we supply
We stock tirzepatide as a lyophilised cake in 10mg, 20mg, 30mg and 60mg amber-glass vials, plus a pre-filled pen format in matching dose strengths, independently HPLC-verified by Janoshik Analytical to 99%+ purity. The Janoshik Certificate of Analysis ships in the box with every order where one is available for the current batch, and the report is also published on our Purity page for independent reference. The product page with current pricing, the integrated dose calculator (built around the SURPASS / SURMOUNT 2.5, 5, 10, 15 mg weekly dose ladder), the research-protocol tabs, and the BAC-water option is at /peptides/tirzepatide.html.
Research use only. The compound information described above is drawn from peer-reviewed analytical and clinical literature and is provided for laboratory and in-vitro research context.